Tango Therapeutics, Inc. $TNGX
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING3
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| TNG260 NCT05887492 |
P1/2 | Active, not recruiting | Non Small Cell Lung Cancer; Solid Tumors, Adult | 126 | 2026-09 (+20 mo) |
| TNG456 NCT06810544 |
P1/2 | Recruiting | Non Small Cell Lung Cancer; Glioma Glioblastoma Multiforme | 191 | 2027-03-31 |
| TNG462 NCT05732831 |
P1/2 | Recruiting | Locally Advanced Solid Tumor | 225 | 2027-06 (+13 mo) |
| TNG462 NCT06922591 |
P1/2 | Recruiting | PDAC; PDAC - Pancreatic Ductal Adenocarcinoma | 183 | 2027-06 |
| vopimetostat NCT07897734 |
P1/2 | Not yet recruiting | PDAC; PDAC - Pancreatic Ductal Adenocarcinoma | 188 | 2031-11 |